Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
43 hedge funds and large institutions have $45.8M invested in Aevi Genomic Medicine Inc in 2015 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
71% more capital invested
Capital invested by funds: $26.8M → $45.8M (+$19M)
53% more call options, than puts
Call options by funds: $164K | Put options by funds: $107K
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
13% more funds holding
Funds holding: 38 → 43 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$943K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$537K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$294K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$287K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$377K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$171K |
| 3 |
WA
WFG Advisors
Dallas,
Texas
|
-$101K |
| 4 |
Jennison Associates
New York
|
-$93.5K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$87K |
GNMX Hedge Fund Activity: Q1 2015 in Review
43 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2015, worth a combined $45.8M — up 71% from $26.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GNMX positions and 4 closed out — a net gain of 5 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $943K. The largest seller was Sphera Funds Management, cutting an estimated $377K.
- 43 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2015, up from 38 in Q4 2014.
- Funds reported $45.8M of Aevi Genomic Medicine Inc stock for Q1 2015, up 71% quarter-over-quarter.
- 9 funds opened new Aevi Genomic Medicine Inc positions in Q1 2015 and 4 closed out, a net change of +5 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q1 2015 was Perceptive Advisors, an estimated $943K added.
- The largest Aevi Genomic Medicine Inc seller in Q1 2015 was Sphera Funds Management, an estimated $377K sold.
Based on aggregated 13F filings for Q1 2015.